DSP-1181, a pharmaceutical drug created by AI technology, has entered phase 1 clinical trials in Japan. This is the first time an AI-made drug has reached this point in the development process.
DSP-1181, designed to treat obsessive-compulsive disorder, is the work of an international partnership between Japan-based Sumitomo Dainippon Pharma and UK-based Exscientia. Exploratory research concluded in less than one year, showing AI’s clear potential to accelerate medical research.
“We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery,” Andrew Hopkins, CEO of Exscientia, said in a prepared statement.
“We are very excited with the results of the joint research that resulted in the development of candidate compounds in a very short time,” Toru Kimura, senior executive research director of Sumitomo Dainippon Pharma, said in the same statement. “We will continue to work hard to make this clinical study a success so that it may deliver new benefits to patients as soon as possible.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.